The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol

Kunihiko Moriya; Toshihiko Imamura; Saori Katayama; Akira Kaino; Kenji Okamoto; Norihumi Yokoyama; Suguru Uemura; Hironobu Kitazawa; Masahiro Sekimizu; Hidefumi Hiramatsu; Ikuya Usami; Hisashi Ishida; Daiichiro Hasegawa; Asahito Hama; Akiko Moriya-Saito; Atsushi Sato; Yoji Sasahara; Souichi Suenobu; Keizo Horibe; Junichi Hara; Japan Association of Childhood Leukemia Study Group (JACLS)

doi:10.1111/bjh.17988

The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol

Br J Haematol. 2022 Mar;196(5):1257-1261. doi: 10.1111/bjh.17988. Epub 2021 Dec 8.

Authors

Kunihiko Moriya¹, Toshihiko Imamura², Saori Katayama¹, Akira Kaino¹, Kenji Okamoto², Norihumi Yokoyama³, Suguru Uemura⁴, Hironobu Kitazawa⁵, Masahiro Sekimizu⁶, Hidefumi Hiramatsu⁷, Ikuya Usami⁸, Hisashi Ishida^{9

10}, Daiichiro Hasegawa⁴, Asahito Hama⁵, Akiko Moriya-Saito¹⁰, Atsushi Sato¹¹, Yoji Sasahara¹, Souichi Suenobu¹², Keizo Horibe⁶, Junichi Hara¹³; Japan Association of Childhood Leukemia Study Group (JACLS)

Affiliations

¹ Department of Pediatrics, Tohoku University Graduate School of Medicine, Sendai, Japan.
² Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
³ Department of Pediatrics, Gifu City Hospital, Gifu, Japan.
⁴ Department of Hematology/Oncology, Hyogo Prefectural Children's Hospital, Kobe, Japan.
⁵ Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
⁶ Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
⁷ Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁸ Department of Pediatric Hematology and Oncology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.
⁹ Department of Pediatrics, Okayama University Hospital, Okayama, Japan.
¹⁰ Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
¹¹ Department of Hematology/Oncology, Miyagi Children's Hospital, Sendai, Japan.
¹² Department of Pediatrics, Faculty of Medicine, Oita University, Yufu, Japan.
¹³ Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.

PMID: 34879431
DOI: 10.1111/bjh.17988

Abstract

In this study, we performed a retrospective analysis of a cohort of Japanese paediatric patients with B-cell precursor (BCP)-acute lymphoblastic leukaemia (ALL) treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol, to clarify the incidence, clinical characteristics, and risk factors of osteonecrosis (ON) in comparison to the ALL-02 protocol. We identified a high frequency of ON with the BFM95-based protocol compared to the ALL-02 protocol. The incidence of symptomatic ON with the BFM95-based protocol is comparable to previous studies in Western countries. We believe that the type of treatment regimen has more impact on the incidence of symptomatic ON in paediatric ALL than ethnicity.

Keywords: Berlin-Frankfurt-Münster (BFM)95-based protocol; Japanese children; acute lymphoblastic leukaemia; osteonecrosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Asparaginase / adverse effects
Asparaginase / therapeutic use
Child
Child, Preschool
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
Cytarabine / adverse effects
Cytarabine / therapeutic use
Daunorubicin / adverse effects
Daunorubicin / therapeutic use
Female
Humans
Incidence
Infant
Japan / epidemiology
Male
Mercaptopurine / adverse effects
Mercaptopurine / therapeutic use
Osteonecrosis / chemically induced*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
Prednisolone / adverse effects
Prednisolone / therapeutic use
Prednisone / adverse effects
Prednisone / therapeutic use
Retrospective Studies
Vincristine / adverse effects
Vincristine / therapeutic use

Substances

Cytarabine
Vincristine
Cyclophosphamide
Prednisolone
Mercaptopurine
Asparaginase
Prednisone
Daunorubicin

Supplementary concepts

ALL-BFM-95 protocol
PVDA protocol